Nectar Lifesciences Intrinsic Value

Nectar Lifesciences intrinsic value. Nectar Lifesciences (NECLIFE) median intrinsic value is ₹19.62 from 8 valuation models (range ₹4–₹29), vs current price ₹9.81 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse NECLIFE FII DII holdings to track promoter, FII and institutional holdings.

Market Price (CMP)
₹9.81
Primary Intrinsic Value
₹12.32
Market Cap
₹18.6 Cr
+100.0% Upside
Median Value
₹19.62
Value Range
₹4 - ₹29
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

NECLIFE Valuation Methods Summary — DCF, Graham Number & P/E

Nectar Lifesciences intrinsic value across 8 models vs current price ₹9.81 — upside/downside and value range per method. For current market price and key ratios, visit Nectar Lifesciences share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹12.32 ₹9.86 - ₹14.78 +25.6% EPS: ₹0.56, Sector P/E: 22x
Book Value Method asset ₹24.53 ₹22.08 - ₹26.98 +150.1% Book Value/Share: ₹306.32, P/B: 2.0x
Revenue Multiple Method revenue ₹19.62 ₹17.66 - ₹21.58 +100.0% Revenue/Share: ₹29.47, P/S: 2.0x
EBITDA Multiple Method earnings ₹19.62 ₹17.66 - ₹21.58 +100.0% EBITDA: ₹28.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹24.53 ₹19.62 - ₹29.44 +150.1% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹3.58 ₹3.22 - ₹3.94 -63.5% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹8.65 ₹7.79 - ₹9.52 -11.8% Revenue Growth: 6.0%, Adj P/E: 15.5x
Graham Defensive Method conservative ₹29.43 ₹26.49 - ₹32.37 +200.0% EPS: ₹0.56, BVPS: ₹306.32
Method Types: Earnings Asset DCF Growth Dividend Conservative

NECLIFE Intrinsic Value vs Market Price — All Valuation Models

Nectar Lifesciences fair value range ₹4–₹29 vs current market price ₹9.81 across 8 valuation models. Browse NECLIFE income statement for revenue, profit, balance sheet and cash flow data.

NECLIFE Intrinsic Value Analysis — Undervalued or Overvalued?

Nectar Lifesciences median intrinsic value ₹19.62, current price ₹9.81 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of NECLIFE?

Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nectar Lifesciences (NECLIFE) is ₹19.62 (median value). With the current market price of ₹9.81, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹3.58 to ₹29.43, indicating ₹3.58 - ₹29.43.

Is NECLIFE undervalued or overvalued?

Based on our multi-method analysis, Nectar Lifesciences (NECLIFE) appears to be trading below calculated value by approximately 100.0%.

NECLIFE Financial Health — Key Ratios vs Industry Benchmarks

Nectar Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 2.1% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin -75200.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 0.09x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

NECLIFE Cash Flow Quality — Operating & Free Cash Flow

Nectar Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹-349 Cr ₹-349 Cr Negative Cash Flow 3/10
March 2025 ₹169 Cr ₹148 Cr Positive Free Cash Flow 8/10
March 2024 ₹225 Cr ₹217 Cr Positive Free Cash Flow 8/10
March 2023 ₹134 Cr ₹134 Cr Positive Free Cash Flow 8/10
March 2022 ₹95 Cr ₹95 Cr Positive Free Cash Flow 8/10